{
    "clinical_study": {
        "@rank": "105970", 
        "arm_group": [
            {
                "arm_group_label": "Arm Cisplatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT"
            }, 
            {
                "arm_group_label": "Arm Nimotuzumab", 
                "arm_group_type": "Experimental", 
                "description": "Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute\n      treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally\n      advanced NPC. Three hundreds and twenty patients will be recruited into this study."
        }, 
        "brief_title": "Phase \u2162 Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Scheme:\n\n      Eligible stage III and IVA/B NPC patients will first be stratified by institution, then\n      randomized to 2 arms at 1:1 ratio.\n\n      - Arm Cisplatin:\n\n      Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every\n      3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT\n\n      - Arm nimotuzumab:\n\n      Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every\n      3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven poorly differentiated or undifferentiated carcinoma of the\n             nasopharynx.\n\n          -  Stage III and IVA/B NPC patients\n\n          -  KPS >70\n\n          -  Age between 18-70\n\n          -  AGC > 2000, platelets > 100,000, AST or ALT<2 x upper normal, serum\n             creatinine<1.5mg/dl, creatinine clearance >50ml/min\n\n        Exclusion Criteria:\n\n          -  Histology other than poorly differentiated or undifferentiated carcinoma, including\n             keratinized squamous cell carcinoma.\n\n          -  Evidence of metastases (below the clavicle or distant) by clinical or radiographic\n             examinations.\n\n          -  Initial surgical treatment excluding diagnostic biopsy of the primary site or neck\n             disease.\n\n          -  Patients with simultaneous or prior malignancy (not include basal cell carcinoma of\n             skin)\n\n          -  Prior radiation treatment to the head and neck or any prior chemotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012062", 
            "org_study_id": "NPC-IMRT-N"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm Cisplatin", 
                    "Arm Nimotuzumab"
                ], 
                "intervention_name": "TPF neoadjuvant chemotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm Cisplatin", 
                "intervention_name": "Concurrent chemotherapy with cisplatin during radiotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm Nimotuzumab", 
                "intervention_name": "Concurrent nimotuzumab during radiotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm Cisplatin", 
                    "Arm Nimotuzumab"
                ], 
                "intervention_name": "Radical radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nasopharyngeal carcinoma", 
            "Neoadjuvant chemotherapy", 
            "Concurrent chemotherapy", 
            "Nimotuzumab"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "konglinj@gmail.com", 
                "last_name": "Lin Kong, MD", 
                "phone": "86 18017312533"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Jiade J Lu, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jianji Pan, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Shaojun Lin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Qin Lin, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Chaosu Hu, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "konglinj@gmail.com", 
            "last_name": "Lin Kong, MD", 
            "phone": "86 18017312533"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Adverse Events (severe radiation-induced skin and mucosal toxicities)", 
            "safety_issue": "Yes", 
            "time_frame": "From Day 1 to Day 90 of radiotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012062"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Lin Kong", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fujian Province Tumor Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First Affiliated  Hospital of Xiamen University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}